AdjuTec is a young biotech company (2017), fully dedicated to the development of personalized therapeutic tumor vaccines for pancreatic and liver cancer patients.

The basic technology has been exclusively licensed from CyTuVax in the gastroenterological domain. AdjuTec will apply patient specific ‘neo-antigens’ derived from frame-shift mutations in the tumor cells of the patient, in combination with depot-formulated cytokines as adjuvant in a personalized cancer vaccination concept. AdjuTec closely cooperates with the MUMC and RWTH UniKlinik Aachen (Center of Cell Biology).

Version: 29/01/2018